PRNewsWire
19 Mar 2026, 14:00 UTC · 26w ago
Verdict
Headline takes no side. We score PEPG −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 96% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
The FDA placed a partial clinical hold on PepGen's FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1 due to concerns over preclinical pharmacology and toxicology studies.
So whatFDA clinical holds on lead drug candidates signify significant regulatory hurdles and potential safety issues, directly threatening the company's pipeline and valuation.
More negative than 98% of claims this week
Pomerantz LLP has launched an investigation into PepGen and its officers for potential securities fraud or unlawful business practices.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 80% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a partial FDA clinical hold and is being investigated for potential securities fraud.
More negative than 88% of ticker scores this week
The company is subject to an investigation by a law firm on behalf of investors.
More negative than 88% of ticker scores this week
The company is subject to an investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
47m ago
−43.3%
Price agrees with the score
$2.90 vs $5.12 close before publication (Mar 18) · not market-adjusted
PEPG chart →
